Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes.
Hiroyuki ItoSuzuko MatsumotoTakuma IzutsuEiji KusanoShinya NishioShinichi AntokuTomoko YamasakiToshiko MoriMichiko ToganeShigenori AndoEmiko TsugamiPublished in: Diabetes, metabolic syndrome and obesity : targets and therapy (2019)
Although renoprotective effects might be limited, empagliflozin can safely and effectively improve metabolic parameters, even in elderly subjects.
Keyphrases